SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.334
EU - Europa 2.161
AS - Asia 1.789
SA - Sud America 7
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.290
CN - Cina 871
UA - Ucraina 586
IT - Italia 443
SG - Singapore 433
TR - Turchia 373
DE - Germania 351
GB - Regno Unito 287
FI - Finlandia 148
SE - Svezia 148
ID - Indonesia 66
BE - Belgio 47
CA - Canada 41
PL - Polonia 41
FR - Francia 39
AT - Austria 38
IN - India 12
IR - Iran 10
VN - Vietnam 8
NL - Olanda 7
CZ - Repubblica Ceca 6
HK - Hong Kong 6
AU - Australia 5
BR - Brasile 5
JP - Giappone 4
LT - Lituania 4
RO - Romania 4
RU - Federazione Russa 4
BG - Bulgaria 2
EU - Europa 2
IE - Irlanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BD - Bangladesh 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
IQ - Iraq 1
KH - Cambogia 1
KR - Corea 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
TW - Taiwan 1
Totale 13.300
Salva come PNG Salva come JPEG
Città #
Fairfield 1.266
Woodbridge 1.234
Houston 683
Ashburn 674
Jacksonville 670
Chandler 666
Ann Arbor 517
Seattle 472
Wilmington 450
Cambridge 415
Singapore 351
Santa Clara 320
Izmir 236
Beijing 227
Nanjing 173
Princeton 165
Ferrara 162
San Diego 114
Boardman 105
Shanghai 99
Milan 80
Jakarta 66
Bremen 65
Shenyang 57
New York 56
Falls Church 48
Brussels 46
Hebei 45
Los Angeles 42
Warsaw 41
Nanchang 38
Vienna 38
Tianjin 35
Changsha 29
Norwalk 29
Jiaxing 28
Munich 27
San Mateo 25
Auburn Hills 24
London 24
Washington 24
Jinan 22
Mountain View 21
Helsinki 20
Redwood City 20
Dearborn 17
Zhengzhou 15
Orange 14
Leawood 13
Mcallen 13
Frankfurt am Main 12
Guangzhou 12
Montréal 12
Ottawa 12
Toronto 12
Addison 11
Lappeenranta 11
Redmond 11
Tappahannock 11
Kunming 10
Verona 10
Des Moines 9
Dong Ket 8
Indiana 8
Ningbo 8
Rome 8
Taizhou 8
Augusta 7
Morciano Di Romagna 7
Ardabil 6
Brno 6
Changchun 6
Hong Kong 6
Monterenzio 6
Fuzhou 5
Bologna 4
Chicago 4
Cordignano 4
Hangzhou 4
Philadelphia 4
Walnut 4
Ferrara di Monte Baldo 3
Kilburn 3
Lanzhou 3
Marsala 3
Mumbai 3
Napoli 3
Pisa 3
Prescot 3
San Francisco 3
Serra 3
Acton 2
Altavilla Vicentina 2
Amsterdam 2
Aurora 2
Bangalore 2
Brindisi 2
Casalecchio di Reno 2
Chiswick 2
Delianuova 2
Totale 10.315
Salva come PNG Salva come JPEG
Nome #
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 200
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 166
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 166
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 156
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 153
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 150
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 144
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 143
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 135
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 131
Loss of cortical GABA terminals in Unverricht–Lundborg disease 130
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 129
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 129
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 128
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 128
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 127
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 127
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 127
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 127
Role of LRRK2 in the regulation of dopamine receptor trafficking 126
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 124
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 124
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 124
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 123
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices. 123
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 121
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 120
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 118
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 118
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 117
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. 117
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 116
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. 116
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 115
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 115
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 115
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 115
null 113
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 113
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 113
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 112
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 112
Antagonisti dei recettori NOP e loro usi terapeutici 111
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 111
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 110
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 110
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 110
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. 109
null 108
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 108
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 108
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 108
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 108
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 107
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 104
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 104
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 104
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 104
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 103
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 100
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 99
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 98
Parkinson's disease: no NOP, new hope 98
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata: A microdialysis study in the awake freely moving rat. 97
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 97
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 95
null 94
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. 93
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 93
null 92
null 92
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 91
null 91
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 90
null 89
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 89
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 89
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 88
null 88
null 87
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance. 87
null 87
NOP receptor ligands and Parkinson’s disease 86
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 86
Autophagy and LRRK2 in the Aging Brain 86
Synthesis and structure activity relationships of delthorphine analogues 85
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 85
null 84
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 84
null 82
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 82
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 81
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 81
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 80
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 78
null 77
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 77
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 70
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 70
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 69
Totale 10.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.402
Totale 68.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.700 0 0 0 0 0 316 266 313 252 282 206 65
2020/20212.004 165 170 94 225 111 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/2025965 74 88 310 82 402 9 0 0 0 0 0 0
Totale 13.509